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hhali et al. (1) raise important points about guidelines and
erformance measures. Although they focus on heart fail-
re, their comments are relevant beyond a single clinical
ondition. We agree with the goal of personalizing patient
are to the extent possible, but we do not believe that
uidelines and performance measures necessarily conflict
ith this important goal. As members of the American
ollege of Cardiology Foundation (ACCF) and American
eart Association (AHA) Task Force on Practice Guide-
ines (TFPG) and Task Force on Performance Measures
TFPM), we welcome the opportunity to discuss our per-
pective on these issues.
linical Practice Guidelines
ince the early 1980s, the ACCF and the AHA have
ngaged in a joint effort to develop clinical practice guide-
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mprove the quality of care and outcomes for patients with
ardiovascular disease and fostered by evidence of substan-
ial variation in rates of adherence to evidence-based ther-
pies. Each guideline represents a summary and synthesis of
he available evidence by a writing committee, which is
etted through an exhaustive process of peer review and
pproval by the TFPG, the Board of Trustees of the ACCF,
nd the Science Advisory Coordinating Committee of the
HA, in addition to the governing bodies of relevant
artnering organizations. Therefore, it is not surprising
hat practice according to ACCF and AHA guidelines
ecommendations is associated with improved patient out-
omes (2,3).
The methods used to collect, evaluate and classify the
vidence adopted by the TFPG are widely known (4,5).
riefly, the recommendations are classified according to
hether a test, procedure, treatment, or strategy is useful
nd effective considering the size of the treatment effect
Class I, IIa, IIb, and III), relying where possible on
andomized clinical trials (RCTs) and according to an
stimate of the certainty (or precision) of the treatment
ffect (Level of Evidence: A, B, or C). Recommendations
ased on limited data, case reports, consensus opinion, or
tandard of care (or on sound clinical judgment where it is
ot feasible to study the issue) are considered Level of
vidence: C.
We agree with the concern of Ghali et al. (1) that we
eed to expand our evidence base to more definitively guide
reatment choices across the spectrum of patient types and
linical scenarios faced in routine practice. The Level
f Evidence: C recommendations, however, reflect the
FPG’s desire to bring together expert consensus opinion
o more fully advise clinicians in common clinical situations
or which limited or no evidence yet exists. Moreover, it is
recisely when evidence is lacking or conflicting that clini-
ians frequently need and request guidance from experts.
We also agree that RCTs, while providing some of the
ost rigorous evidence for therapies in selected populations,
ave important limitations. This view is incorporated into
he TFPG methodology. Each RCT that is reviewed,
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Responsible Guidance and Accountability December 14/21, 2010:2081–3specially if it informs a recommendation, is evaluated for
uality and overall consistency with existing evidence base.
ften the limitations of a study are reflected in the specific
anguage of the recommendation or in the accompanying
ext (such as the recommendation for implantable
ardioverter-defibrillator placement for patients with left
entricular systolic dysfunction, which recommends that
mplantation only be considered in patients with a “reason-
ble expectation of survival with a good functional status for
ore than 1 year”) (6). We also recognize the trade-off
etween internal validity (of a RCT) and external validity or
eneralizability (of a registry or clinical practice experience),
ut in view of the known limitations of (even pre-specified)
ubgroup analyses (7), specific subgroups are usually not
ulled out of any recommendation absent robust data to
upport this approach. When available, the committees also
onsider whether trial results from select population are also
upported by comparative effectiveness evaluations in
roader observational registries. Where evidence exists,
pecific sections in the guideline will address the elderly,
atients with diabetes, women, and others. Yet in general,
atients are typically more similar than they are different.
hen studied in sufficient numbers of patients, true differ-
nces in treatment effectiveness or safety are rare. As a
esult, the TFPG appropriately does not recommend dif-
erential therapy for women or the elderly simply on the
asis of hypothesis-generating subgroup analyses from
CTs.
Given these considerations, the preamble to every guide-
ine states that these statements are intended as general
uides and that patient care decisions are ultimately to be
ade by the treating clinician in view of all of the circum-
tances presented by a specific patient. The preamble also
tates that prescribed courses of treatment in accordance
ith recommendations are effective only if they are fol-
owed. Lack of patient adherence or a failure of clinicians to
eliver or monitor an indicated therapy may adversely affect
utcomes. Therefore, physicians and patients must work
ogether to promote optimal and safe treatment regimens
nd lifestyle changes.
Finally, we realize that the guideline process is not
erfect. Rather, it is iterative, and currently, changes to the
vidence review, a specific evidence scoring system, the
ddition of Bayesian analysis, and shorter formats are being
valuated as enhancements to the process. These innova-
ions will be described in an upcoming publication. We
elieve that these changes will improve the extent to which
uidelines reflect existing evidence and facilitate translation
f guidelines in practice.
erformance Measures
ith respect to performance measures, we agree that not all
uideline recommendations are appropriate for performance
easurement. Indeed, as Ghali et al. (1) point out, althoughhe heart failure guideline contains dozens of Class I oecommendations, a select few of these processes of care
ave been incorporated into performance measures. The
trongest evidence base, while necessary for the develop-
ent of performance measures, is by no means sufficient. As
elineated in detailed methodology developed by the
FPM, performance measures must also be valid, reliable,
ctionable, and measurable, and they must address a de-
onstrable gap in care (8). The TFPM has also developed
ethodology beyond processes of care, delineating detailed
best practices” for the development of measures of out-
omes (9) and efficiency (10) and for composite measures
11). Thus, although the strongest guideline recommenda-
ions define candidates for performance measurement, only
hose processes that meet a number of other criteria will
ltimately be considered appropriate for the purposes of
ccountability after the application of an explicit and rigor-
us methodology.
The TFPM also has supported the use of clinical exclu-
ions in all process measures as a means of avoiding the
otentially hazardous overuse of therapies in patients with
ontraindications (8,12). Specifically, for all process mea-
ures, explicit clinician documentation of a reason for not
roviding a therapy results in an exclusion, thus removing
ny incentive to provide therapies in patients who are not
deal candidates. Although payers and consumer groups do
ot necessarily share the perspective that these exclusions
re necessary, the TFPM considers this characteristic as
undamental to the validity and acceptability of measures of
rocesses of care (8,12). The assertion that performance
easures diminish the vital role of physician judgment and
nsight into patient management does not account for this
mportant methodological precept of ACCF and AHA
erformance measure development. ACCF and AHA per-
ormance measures are in fact designed to encourage clini-
ians to consider whether a therapy is indicated and not
ontraindicated in each patient, functioning as simultaneous
timuli to reduce both underuse and overuse of therapies.
Additionally, the TFPM strongly advocates the testing of
ts measures in practice to further assess their validity and
eliability, to determine the burden of data collection, and to
dentify unintended consequences of measure implementa-
ion. The capacity to perform such testing has been con-
ucted both in collaboration with outside organizations
e.g., the Centers for Medicare and Medicaid Services) and
ith the registry programs of the ACCF and AHA.
ltimately, this testing is necessary to determine the impact
f measures on practice and patient outcomes.
Finally, as individuals actively involved in clinical prac-
ice, we are acutely aware of the frustrations and anxiety that
erformance measurement can engender. However, we are
lso cognizant that U.S. health care has moved beyond the
uestion of whether performance should be measured; the
ocus now is how measurement will be conducted. Faced
ith the decision to shun performance measurement or to
ake an active role in it, the ACCF and AHA, in our
pinion wisely, chose to engage. Because of this decision,
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December 14/21, 2010:2081–3 Responsible Guidance and Accountabilityhe ACCF and AHA have been able to play an important
ole at the national level in advocating that the measurement
f quality in cardiovascular disease and stroke adheres to
igorous methodology. As professionals, we believe we have
n obligation to define best practices on the basis of the
vidence, to measure how consistently these practices are
eing used in our patients, and to stimulate future quality
mprovement efforts that promote safe and effective care and
aximally improve patient outcomes.
ndustry, Guidelines, and Performance Measures
he ACCF and AHA share the concern voiced by Ghali et
l. (1) about the potential conflicts of interest from industry
n the development of guideline and performance measures.
ecognizing this, the ACCF and AHA have an explicit,
nd relatively stringent, policy on relationships with indus-
ry and other entities for writing group membership, includ-
ng restrictions on the number of writing group members
ho can have relevant conflicts and restricting the writ-
ng and voting on specific sections of the documents to
hose individuals without relationships relevant to these
ections (13).
onclusions
he ACCF and AHA TFPG and TFPM are aware of the
ap between “what we truly know, what we think we know,
nd what we would like to know.” This gap is the precise
eason for the characterization of the level of evidence in
uideline recommendations, for the approach to writing
ecommendations, for the reluctance to generate recom-
endations concerning subgroups without adequate sup-
orting evidence, and for the methodical process to deter-
ine which Class I guideline recommendations qualify for
onsideration of performance measures. We believe that
uidelines and performance measures generated by the
CCF and AHA provide clinicians with methodologically
igorous and practical tools to support their practice. We are
ommitted to continually evolving and updating both the
evelopment process as well as the documents themselves.
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